Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Director | January 01, 2019 | January 02, 2019 |
| Evolus, Inc.EOLS · Entity 5341 | Director | January 27, 2023 | February 01, 2023 |
| RESMED INCRMD · Entity 2692 | Director | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Arcturus Therapeutics Ltd.
Report date January 01, 2019 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 86,452 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 86,452 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Vesting monthly over a two year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
F2: Vesting monthly over a two year period from August 24, 2018.
F3: Vesting monthly over a one year period from August 24, 2018.
Evolus, Inc.
Report date January 27, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,174 |
Reported balance
After 2023-01-27 transaction · row 1
1 source rowRow 1 · 2023-01-27 · Grant · Acquired 8,293 · Balance 43,174 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.25 · Expires 2033-01-27 | Direct | 11,789 |
Reported balance
After 2023-01-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-27 · Grant · Acquired 11,789 · Balance 11,789 F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 10,000 |
Reported balance
Holding disclosure · report date 2023-01-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer
F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
RESMED INC
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 51,803 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 970 · Balance 51,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date May 03, 2018 · Filed May 07, 2018
Section 16 reporting ended · disclosed 2018-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 36,713 |
Last balance in matching sequence
After 2018-05-03 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2018-05-03 · Exercise / conversion · Acquired 16,844 · Balance 35,490 F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 2 · 2018-05-03 · Exercise / conversion · Acquired 6,000 · Balance 41,490 F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 3 · 2018-05-03 · Tax withholding · Disposed 4,777 · Balance 36,713 F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-03 · Exercise / conversion · Disposed 3,725 · Balance 0 F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-03 · Exercise / conversion · Disposed 2,501 · Balance 0 F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-03 · Exercise / conversion · Disposed 2,822 · Balance 0 F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-03 · Exercise / conversion · Disposed 2,130 · Balance 0 F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2018-05-22 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-03 · Exercise / conversion · Disposed 6,000 · Balance 0 F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired.
F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards.
F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise.
F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested.
F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested.
F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested.
F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested.
F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested.
F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested.
F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 10:30 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 970 | $234.73 | $227,688.10 |
DisclosureSEC source: 0000943819-26-000050 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,803 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| August 05, 2026 Filed Aug 6, 2026 18:29 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,000 | $225.00 | $1,800,000.00 |
DisclosureSEC source: 0000943819-26-000040 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| June 05, 2026 Filed Jun 15, 2026 21:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001193805-26-000828 · e665583_4-farrell.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-05 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 17:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $225.00 | $450,000.00 |
DisclosureSEC source: 0000943819-26-000019 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 19:51 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $260.22 | $520,440.00 |
DisclosureSEC source: 0000943819-26-000014 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:07 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $251.31 | $502,620.00 |
DisclosureSEC source: 0000943819-26-000010 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 12:33 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $248.83 | $497,660.00 |
DisclosureSEC source: 0000943819-26-000004 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 18:46 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $251.47 | $502,940.00 |
DisclosureSEC source: 0000943819-25-000186 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 20:26 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 1,331 | $250.52 Strike: $250.52 | $333,442.12 |
DisclosureSEC source: 0000943819-25-000182 · form4.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,331 Underlying: ResMed Common Stock · 1,331 shares Expires 2032-11-11 F1 · derivative.exercise_date: Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:39 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000164 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,773 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 11,442 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000122 · form4.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 11,442 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:59 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 7,314 | $244.46 | $1,787,980.44 |
DisclosureSEC source: 0000943819-25-000122 · form4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,238 F2 · kind: Disposition to issuer for tax withholding and cost to exercise the options granted on 11/14/2018. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 11,442 | $101.64 | $1,162,964.88 |
DisclosureSEC source: 0000943819-25-000122 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 22:39 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $252.05 | $504,100.00 |
DisclosureSEC source: 0000943819-25-000117 · form4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,110 F2 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:39 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 162.953 | $250.10 | $40,754.55 |
DisclosureSEC source: 0000943819-25-000117 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,110 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 16:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 945 | $255.49 | $241,438.05 |
DisclosureSEC source: 0000943819-25-000026 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,273 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 00:02 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001193805-25-000878 · e664624_4-farrell.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-09 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 19:22 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $247.32 | $494,640.00 |
DisclosureSEC source: 0000943819-25-000013 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| May 07, 2025 Filed May 8, 2025 21:38 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $242.25 | $484,500.00 |
DisclosureSEC source: 0001127602-25-013743 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 16:47 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $219.74 | $439,480.00 |
DisclosureSEC source: 0001127602-25-011625 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:40 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $227.71 | $455,420.00 |
DisclosureSEC source: 0001127602-25-008593 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| February 05, 2025 Filed Feb 5, 2025 21:49 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $242.11 | $484,220.00 |
DisclosureSEC source: 0001127602-25-003232 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:57 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $230.99 | $461,980.00 |
DisclosureSEC source: 0001127602-25-000487 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 23:44 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $245.65 | $491,300.00 |
DisclosureSEC source: 0001127602-24-028741 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 00:49 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 1,468 | $249.56 Strike: $249.56 | $366,354.08 |
DisclosureSEC source: 0001127602-24-028139 · form4.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,468 Underlying: ResMed Common Stock · 1,468 shares Expires 2031-11-25 F1 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:01 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 542 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027893 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,218 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 23:01 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 527.905 | $252.38 | $133,232.66 |
DisclosureSEC source: 0001127602-24-027102 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,676 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 18:15 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $248.74 | $497,480.00 |
DisclosureSEC source: 0001127602-24-026799 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| October 02, 2024 Filed Oct 2, 2024 20:20 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $237.20 | $474,400.00 |
DisclosureSEC source: 0001127602-24-024898 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 19:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $239.90 | $479,800.00 |
DisclosureSEC source: 0001127602-24-023609 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000824 · e663725_4-farrell.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-14 F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionDeferred Stock Units · Derivative | 3,131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000824 · e663725_4-farrell.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,131 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionCommon Stock | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000824 · e663725_4-farrell.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| May 15, 2024 Filed May 17, 2024 15:29 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 68,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015779 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,204 F1 · kind: Represents a gift of shares to Bank of America, N.A. Successor Trustee of Peter C. Farrell Charitable Remainder Trust. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 23:40 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 10,935 | $182.66 | $1,997,434.12 |
DisclosureSEC source: 0001127602-24-006731 · form4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,404 F2 · price: This transaction was executed in multiple trades at prices ranging from $182.41 - $183.07. The price reported above reflects the weighted average sale price. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 23:50 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028045 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,939 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 00:00 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 325.375 | $143.60 | $46,723.85 |
DisclosureSEC source: 0001127602-23-027459 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,171 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:12 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantDeferred Stock Units · Derivative | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-23-001073 · e618811_4-farrell.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,131 Underlying: Common Stock · 3,131 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock. F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:12 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 11,869 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001193805-23-001073 · e618811_4-farrell.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,869 Underlying: Common Stock · 11,869 shares Expires 2033-08-01 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| May 03, 2023 Filed Feb 23, 2024 23:40 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 12,600 | $237.17 | $2,988,374.76 |
DisclosureSEC source: 0001127602-24-006731 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,896 F1 · price: This transaction was executed in multiple trades at prices ranging from $236.40 - $237.94. The price reported above reflects the weighted average sale price. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 01:40 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 11,789 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0001570562-23-000020 · wf-form4_167521563026338.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,789 Underlying: Common Stock · 11,789 shares Expires 2033-01-27 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 01:40 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 8,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-23-000020 · wf-form4_167521563026338.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,174 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:18 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026046 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,496 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:14 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 128 | $225.18 | $28,823.04 |
DisclosureSEC source: 0001127602-22-025653 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,374 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:23 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 4,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024789 · form4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,502 F2 · kind: Represents a gift of shares to Bank of America, N.A. Successor Trustee of Peter C. Farrell Charitable Remainder Unitrust. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:23 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 9,050 | $221.98 | $2,008,877.37 |
DisclosureSEC source: 0001127602-22-024789 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,052 F1 · price: This transaction was executed in multiple trades at prices ranging from $217.65 to $224.11. The price reported above reflects the weighted average sale price. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 00:03 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock | 10,000 | $9.10 | $91,048.00 |
DisclosureSEC source: 0001570562-22-000127 · wf-form4_166250899349421.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 10,000 F1 · price: The shares were purchased in multiple trades at prices ranging from $9.02 to $9.18. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: By Peter C. Farrell Trust Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:16 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001193805-22-001024 · e621785_4-farrell.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:01 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 22,727 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000048 · wf-form4_164324885895783.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:01 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 15,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000048 · wf-form4_164324885895783.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,881 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 24, 2022, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.